Skip to main content
. 2022 Sep 26;13:1000626. doi: 10.3389/fimmu.2022.1000626

Figure 2.

Figure 2

The 24 h dynamic change of PLR after rtPA in patients. (A) Patients in total. (B) Patients with favorable (mRS ≤ 2) or poor (mRS>2) outcome. (C) Patients with alive or dead status. PLR, platelet-to-lymphocyte ratio; rtPA, recombinant tissue plasminogen activator; mRS, Modified Rankin Scale. **P<0.01; ***P<0.001.